Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/166338
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVieira, Raquel-
dc.contributor.authorSouto, Selma B.-
dc.contributor.authorSánchez-López, E. (Elena)-
dc.contributor.authorLópez-Machado, Ana-
dc.contributor.authorSeverino, Patrícia-
dc.contributor.authorJose, Sajan-
dc.contributor.authorSantini, Antonello-
dc.contributor.authorFortiuna, Ana-
dc.contributor.authorGarcía López, María Luisa-
dc.contributor.authorSilva, Amélia M.-
dc.contributor.authorSouto, Eliana B.-
dc.date.accessioned2020-06-19T14:32:20Z-
dc.date.available2020-06-19T14:32:20Z-
dc.date.issued2019-10-10-
dc.identifier.issn1424-8247-
dc.identifier.urihttp://hdl.handle.net/2445/166338-
dc.description.abstractDiabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia together with disturbances in the metabolism of carbohydrates, proteins and fat, which in general results from an insulin availability and need imbalance. In a great number of patients, marketed anti-glycemic agents have shown poor effectiveness in maintaining a long-term glycemic control, thus being associated with severe adverse effects and leading to an emerging interest in natural compounds (e.g., essential oils and other secondary plant metabolites, namely, flavonoid-rich compounds) as a novel approach for prevention, management and/or treatment of either non-insulin-dependent diabetes mellitus (T2DM, type 2 DM) and/or Metabolic Syndrome (MS). In this review, some of these promising glucose-lowering agents will be comprehensively discussed-
dc.format.extent31 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherMDPI-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/ph12040152-
dc.relation.ispartofPharmaceuticals, 2019, vol. 12, num. 4, p. 152-
dc.relation.urihttps://doi.org/10.3390/ph12040152-
dc.rightscc-by (c) Vieira, Raquel et al., 2019-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es-
dc.sourceArticles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)-
dc.subject.classificationDiabetis no-insulinodependent-
dc.subject.classificationSíndrome metabòlica-
dc.subject.classificationFitoteràpia-
dc.subject.classificationFarmacologia-
dc.subject.classificationGlucèmia-
dc.subject.otherNon-insulin-dependent diabetes-
dc.subject.otherMetabolic syndrome-
dc.subject.otherPhytotherapy-
dc.subject.otherPharmacology-
dc.subject.otherBlood sugar-
dc.titleSugar-lowering drugs for type 2 Diabetes Mellitus and Metabolic Syndrome Review of cassical and new compounds: Part-I-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec701302-
dc.date.updated2020-06-19T14:32:20Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid31658729-
Appears in Collections:Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
Articles publicats en revistes (Institut de Nanociència i Nanotecnologia (IN2UB))

Files in This Item:
File Description SizeFormat 
701302.pdf1.21 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons